Moderna Announces Positive Phase 3 Data for Combination …
Jun 10, 2024 · mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older.
Moderna says Covid-flu combination vaccine shows positive …
Jun 10, 2024 · On Monday, vaccine maker Moderna announced positive late-stage trial results for its Covid-flu combination vaccine it calls mRNA-1083.
Moderna says mRNA flu shot generates better immune response in ... - CNN
Sep 13, 2023 · Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine...
Moderna reports flu and COVID-19 vaccine phase 3 study results - USA TODAY
Jun 10, 2024 · Moderna said Monday that its combination vaccine against flu and COVID-19 drew a greater immune response in late-stage study results than two comparable vaccines on the market.
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, …
Oct 4, 2023 · mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines. Company to begin Phase 3 trial of mRNA-1083 in adults 50 years and above.
Moderna Announces Updates on Pandemic Influenza Program
CAMBRIDGE, MA / January 17, 2025 / Moderna, Inc. (NASDAQ: MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA ...
HHS Provides $590 Million to Accelerate Pandemic Influenza ... - HHS.gov
Jan 17, 2025 · This funding allows Moderna to accelerate development of an H5N1 mRNA influenza vaccine that is well matched to strains currently circulating in cows and birds and expands the clinical data supporting the use of mRNA vaccines that may be needed if other influenza strains emerge with pandemic potential. “Avian flu variants have proven to be ...
After initial stumbles, Moderna gets clean win for mRNA flu shot
Sep 13, 2023 · After tweaking the formula behind an mRNA flu vaccine, Moderna has finally met all the goals needed for a successful shot in a phase 3 trial. Now, CEO Stéphane Bancel is eyeing a launch as early...
Moderna's two-in-one flu and Covid vaccine passes advanced trial
Jun 10, 2024 · Drug company Moderna says its combined flu and Covid vaccine, which targets the two diseases in a single shot, has passed a vital part of final-stage scientific checks. The phase-three trial...
Moderna Announces Interim Phase 3 Safety and Immunogenicity …
Feb 16, 2023 · Moderna is advancing a portfolio of five influenza vaccine candidates that include additional HA antigens for broader coverage of circulating influenza A strains (mRNA-1011 and mRNA-1012) and candidates that incorporate both HA and neuraminidase (NA) antigens to target multiple proteins involved in the influenza virus lifecycle to reduce the pot...